Results 21 to 30 of about 88,356 (287)

AJICAP Second Generation: Improved Chemical Site-Specific Conjugation Technology for Antibody-Drug Conjugate Production

, 2023
The site-directed chemical conjugation of antibodies remains an area of great interest and active efforts within the antibody-drug conjugate (ADC) community.
Muneki, Isokawa, Sayaka, Kawaguchi, Tatsuya, Okuzumi, Yuri, Ooba, Rika, Takasugi, Yutaka, Matsuda, Natsuki, Shikida, Kazutaka, Shimbo, Tomohiro, Fujii, Tomohiro, Watanabe, Akira, Nakayama, Kei, Yamada, Takuya, Seki, Yusuke, Iwai, Noriko, Hatada, Brian. A., Mendelsohn, Kazutoshi, Takahashi   +16 more
core   +1 more source

Antibody-Drug Conjugate-Induced Pneumonitis: A Growing Threat [PDF]

Journal of Immunotherapy and Precision Oncology
Kathy L. Chan, Saadia A. Faiz, Ajay Sheshadri   +2 more
doaj   +2 more sources

Antibody-Drug Conjugates [PDF]

Journal of Nihon University Medical Association, 2017
Abstract Antibody–drug conjugates (ADCs) are designed with the purpose of delivering small-molecule cytotoxic drug to antigen-expressing tumor cells by harnessing the specificity, biodistribution, and pharmacokinetics of antibodies. ADCs are comprised of three components: the antibody, the linker, and the cytotoxic agent.
Amit Kumar, Jason White, R. James Christie, Nazzareno Dimasi, Changshou Gao   +4 more
  +5 more sources

Pneumococcal antibody concentrations and carriage of pneumococci more than 3 years after infant immunization with a pneumococcal conjugate vaccine. [PDF]

, 2012
BACKGROUND: A 9-valent pneumococcal conjugate vaccine (PCV-9), given in a 3-dose schedule, protected Gambian children against pneumococcal disease and reduced nasopharyngeal carriage of pneumococci of vaccine serotypes.
Greenwood, Brian M, Godwin C. Enwere, Brown J Okoko, Nsekpong, Ekpedeme D, Godwin C Enwere, Ekpedeme D Nsekpong, Syed M. A. Zaman, Aderonke A. Odutola, Saaka, Mark, Zaman, Syed MA, Akinsola, Adebayo K, Richard A. Adegbola, Syed M A Zaman, Adebayo K. Akinsola, Aderonke A Odutola, Richard A Adegbola, Martin O. C. Ota, Okoko, Brown J, Odutola, Aderonke A, Martin O C Ota, Cutts, Felicity T, Felicity T Cutts, Ekpedeme D. Nsekpong, Felicity T. Cutts, Adebayo K Akinsola, Brown J. Okoko, Enwere, Godwin C, Brian M Greenwood, Mark Saaka, Adegbola, Richard A, Brian M. Greenwood, Ota, Martin OC   +31 more
core   +1 more source

A disruptive clickable antibody design for the generation of antibody-drug conjugates

, 2023
298310Background: Antibody-drug conjugates are cancer therapeutics that combine specificity and toxicity. A highly cytotoxic drug is covalently attached to an antibody that directs it to cancer cells. The conjugation of the drug-linker to the antibody is
Miriam-Kousso Assi, Simon K Krebs, Stech, Marlitt, Rakotoarinoro, Nathanaël, Krebs, Simon, Nathanaël Rakotoarinoro, Yan F K Dyck, Maria K Parr, Dyck, Yan F.K., Parr, Maria K., Marlitt Stech, Assi, Miriam-Kousso   +11 more
core   +1 more source

Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models

Haematologica, 2020
Antibody drug conjugates represent an important class of anti-cancer drugs in both solid tumors and hematological cancers. Here, we report preclinical data on the anti-tumor activity of the first-in-class antibody drug conjugate MEN1309/OBT076 targeting
Eugenio Gaudio, Chiara Tarantelli, Filippo Spriano, Francesca Guidetti, Giulio Sartori, Roberta Bordone, Alberto J. Arribas, Luciano Cascione, Mario Bigioni, Giuseppe Merlino, Alessio Fiascarelli, Alessandro Bressan, Afua Adjeiwaa Mensah, Gaetanina Golino, Renzo Lucchini, Elena Bernasconi, Davide Rossi, Emanuele Zucca, Georg Stussi, Anastasios Stathis, Robert S. Boyd, Rachel L. Dusek, Arnima Bisht, Nickolas Attanasio, Christian Rohlff, Andrea Pellacani, Monica Binaschi, Francesco Bertoni   +27 more
doaj   +1 more source

"In vitro" and "in vivo" drug targeting using biotinylated immunoliposomes [PDF]

, 2005
The aim of my thesis was the optimization, characterization and application of a new, innovative drug carrier system which can be used to target pharmaceuticals to diseased tissues and organs.
Schnyder, Anita
core   +1 more source

A Trial of a 7-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults. [PDF]

, 2010
BACKGROUND: Streptococcus pneumoniae is a leading and serious coinfection in adults with human immunodeficiency virus (HIV) infection, particularly in Africa.
Zijlstra, EE, Molyneux, Malcolm E, White, Sarah A., Mwaiponya, Martin, Mwalukomo, Thandie, Gordon, Stephen, Zijlstra, Eduard E, Longwe, Herbert, French, N, Mwalukomo, T, White, SA, French, Neil, Gordon, SB, Mwaiponya, M, Gilks, CF, Gilks, Charles F, Mwafulirwa, Gershom, Molyneux, Malcolm E., Mwafulirwa, G, Molyneux, ME, Gordon, Stephen B., Gordon, Stephen B, White, Sarah; id_orcid, Longwe, H, Gilks, Charles F., White, Sarah A, Zijlstra, Eduard E.   +26 more
core   +1 more source

Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates

Nature Communications, 2020
Antibody-drug conjugates targeting high expression receptors can suffer from poor tumour penetration. Here, the authors use unconjugated antibody to improve the penetration of an antibody-dye conjugate in a clinical study, supporting further clinical ...
Guolan Lu, Naoki Nishio, Nynke S. van den Berg, Brock A. Martin, Shayan Fakurnejad, Stan van Keulen, Alexander D. Colevas, Greg M. Thurber, Eben L. Rosenthal   +8 more
doaj   +1 more source

Antibody–Drug Conjugates for Cancer Therapy [PDF]

Biomedicines, 2016
Antibody–drug conjugates (ADCs) take advantage of the specificity of a monoclonal antibody to deliver a linked cytotoxic agent directly into a tumour cell. The development of these compounds provides exciting opportunities for improvements in patient care. Here, we review the key issues impacting on the clinical success of ADCs in cancer therapy.
Adam Parslow, Sagun Parakh, Fook-Thean Lee, Hui Gan, Andrew Scott   +4 more
openaire   +4 more sources